ORLANDO - Nutriband Inc. (NASDAQ:NTRB), specializing in transdermal pharmaceutical products, has advanced its collaboration with Kindeva Drug Delivery by entering into a commercial development and clinical supply agreement. This partnership is set to expedite the development of AVERSA™ Fentanyl, Nutriband's lead product with abuse-deterrent properties.
The agreement, announced today, tasks Kindeva with the commercial manufacturing process development and the production of clinical supplies for the upcoming human abuse liability study, a step required by the FDA for a New Drug Application (NDA). This move signifies a progression from their prior feasibility agreement and aims to harness Kindeva's expertise in transdermal drug delivery for the AVERSA™ technology.
AVERSA™ Fentanyl, which merges Nutriband's proprietary abuse-deterrent technology with Kindeva's FDA-approved transdermal fentanyl system, aspires to be the first opioid patch designed to deter abuse. The product's market potential in the US is projected to peak between $80M and $200M annually, according to a Health Advances market analysis report from 2022.
Gareth Sheridan, CEO of Nutriband, emphasized the importance of the agreement in bringing AVERSA™ Fentanyl swiftly to market and highlighted the technology's potential to enhance the safety of drugs prone to abuse, ensuring their availability for patients in genuine need.
Kindeva's Global Chief Commercial Officer, David Stevens, acknowledged the positive impact of transdermal drug delivery on patient health outcomes and commended the shared development efforts with Nutriband.
Nutriband's AVERSA™ abuse-deterrent technology is designed to integrate aversive agents into transdermal patches, aiming to prevent abuse, diversion, misuse, and accidental drug exposure. The technology is supported by a robust intellectual property portfolio with patents granted in multiple jurisdictions, including the United States and Europe.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.